BMS-274
A Phase 3 Randomized, Double-Blind, Multi-Center Study of Adjuvant Nivolumab versus Placebo in Subjects with High-Risk Invasive Urothelial Carcinoma (CA209-274).
More Information
NILE
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE)
More Information
SGN-22E-002
A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer (EV-103)
More Information
S1600
A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
More Information
A031702
A Phase II Study of Ipilimumab, CabOzantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)
More Information
